Leonard W. Seymour

Leonard W. Seymour Leonard W. Seymour is a Professor of Gene Therapy at the University of Oxford's oncology department. As a cancer-oriented translational researcher, he investigates technologies utilised to enhance targeted therapy's (e.g. drugs, genes, oncolytic virus) delivery and develops related biological therapeutics under the support of Cancer Research UK. Provided by Wikipedia
Showing 1 - 11 results of 11 for search 'Leonard W. Seymour', query time: 0.04s Refine Results
  1. 1
    AAV production in stable packaging cells requires expression of adenovirus 22/33K protein to allow episomal amplification of integrated rep/cap genes

    AAV production in stable packaging cells requires expression of adenovirus 22/33K protein to allow episomal amplification of integrated rep/cap genes by Weiheng Su, Leonard W. Seymour, Ryan Cawood

    Published 2023-12-01
    Get full text
    Article
  2. 2
    The implications of oncolytic viruses targeting fibroblasts in enhancing the antitumoural immune response

    The implications of oncolytic viruses targeting fibroblasts in enhancing the antitumoural immune response by Ibrahem Al-Obaidi, Ciaran Sandhu, Bilal Qureshi, Leonard W. Seymour

    Published 2024-10-01
    Get full text
    Article
  3. 3
    Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?

    Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent? by Peter Kok-Ting Wan, Ricardo A Fernandes, Leonard W Seymour

    Published 2023-08-01
    Get full text
    Article
  4. 4
    A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation.

    A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation. by Thomas Hills, Phillip G Jakeman, Robert C Carlisle, Paul Klenerman, Leonard W Seymour, Ryan Cawood

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination

    Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination by Weiheng Su, Maria I. Patrício, Margaret R. Duffy, Jakub M. Krakowiak, Leonard W. Seymour, Ryan Cawood

    Published 2022-03-01
    Get full text
    Article
  6. 6
    Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells.

    Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. by Ryan Cawood, Hannah H Chen, Fionnadh Carroll, Miriam Bazan-Peregrino, Nico van Rooijen, Leonard W Seymour

    Published 2009-05-01
    Get full text
    Article
  7. 7
    Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy

    Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy by Hena Khalique, Richard Baugh, Arthur Dyer, Eleanor M. Scott, Sally Frost, Sarah Larkin, Janet Lei-Rossmann, Leonard W. Seymour

    Published 2021-04-01
    Get full text
    Article
  8. 8
    Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells

    Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells by Daniel Ebner, Olaf Ansorge, Hena Khalique, Richard Baugh, Janet Lei-Rossmann, Emma Page, Peter Kok-Ting Wan, Leonard W Seymour, Timothy Johanssen

    Published 2024-05-01
    Get full text
    Article
  9. 9
    Nanomedicines for the Delivery of Biologics

    Nanomedicines for the Delivery of Biologics by John Wahlich, Arpan Desai, Francesca Greco, Kathryn Hill, Arwyn T. Jones, Randall J. Mrsny, Gianfranco Pasut, Yvonne Perrie, F. Philipp Seib, Leonard W. Seymour, Ijeoma F. Uchegbu

    Published 2019-05-01
    Get full text
    Article
  10. 10
    Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies

    Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies by Joshua D Freedman, Joachim Hagel, Eleanor M Scott, Ioannis Psallidas, Avinash Gupta, Laura Spiers, Paul Miller, Nikolaos Kanellakis, Rebecca Ashfield, Kerry D Fisher, Margaret R Duffy, Leonard W Seymour

    Published 2017-06-01
    Get full text
    Article
  11. 11
    Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

    Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators by Arthur Dyer, Ying Di, Hugo Calderon, Sam Illingworth, Gray Kueberuwa, Alison Tedcastle, Phil Jakeman, Suet Lin Chia, Alice Brown, Michael A. Silva, David Barlow, John Beadle, Terry Hermiston, David J.P. Ferguson, Brian Champion, Kerry D. Fisher, Leonard W. Seymour

    Published 2017-03-01
    Get full text
    Article

Search Tools: